- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04496882
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue (CHANGE)
The Clinical Efficacy of Tenofovir Alafenamide-switching Therapy in Patients With Chronic Hepatitis B Experiencing Clinical Flare-up After Discontinuation of Nucleos[t]Ide Analogues Therapy
We will conduct a phase 4, multicenter, open-label trial at 7 academic centers in Taiwan.
Chronic hepatitis B patients receiving oral antiviral therapy (entecavir [ETV], tenofovir disoproxil fumarate [TDF]) for at least 2 years, and fulfil the following nucleos(t)ide analogs discontinuation criteria. After nucleos(t)ide analogs discontinuation, patients had a clinical relapse and retreatment regimen switches to TAF.
The protocol will be approved by Institutional Review Board (IRB) or Research ethic committee (REC) of each site and will be conducted in accordance with the principles of Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice. Each patient provides written informed consent before enrollment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Tenofovir alafenamide (TAF) is a new generation of oral antiviral drugs with similar antiviral activities to tenofovir disoproxil fumarate (TDF) and reduces the adverse effects of nephrotoxicity and bone mineral density reduction. This drug has already been reimbursed by National Health Insurance, and can be used for the treatment of patients with chronic hepatitis B.
This is a single-arm prospective clinical trial to enroll patients who discontinued entecavir (ETV) and tenofovir disoproxil fumarate (TDF) and experienced a clinical hepatitis flare up. They can be retreated with TAF for 48 weeks without postponing a 3-month observation period for alanine aminotransferase (ALT) level. The virological control, ALT level recovery, and changes in liver fibrosis, hepatitis B surface antigen, hepatitis B core-associated antigen, and renal function will be observed during retreatment. In addition, a group of patients with the same characteristics who received retreatment with entecavir or TDF will be collected as a control group for comparison. We believe this study can help us understand the clinical benefits of switching to TAF for retreatment after hepatitis flare in patients to discontinue oral antiviral agents.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Tung-Hung Su, MD, PhD
- Phone Number: 886972651694
- Email: tunghungsu@gmail.com
Study Contact Backup
- Name: Pei-Ying Yang, MS
- Phone Number: 886965277228
- Email: pying0208@gmail.com
Study Locations
-
-
-
Chiayi City, Taiwan
- Recruiting
- Buddhist Tzu Chi General Hospital, Da-Lin Branch
-
Contact:
- Kuo-Chih Tseng, MD
- Phone Number: 3240 88652648000
- Email: tsengkuochih@gmail.com
-
Chiayi City, Taiwan
- Recruiting
- Chia-Yi Christian Hospital
-
Contact:
- Chi-Yi Chen, MD
- Phone Number: 5264 88652765041
- Email: 5137ccy@gmail.com
-
Douliu, Taiwan
- Recruiting
- National Taiwan University Hospital, Yun-Lin Branch
-
Contact:
- Yu-Jen Fang, MD
- Phone Number: 886972655715
- Email: toby851072@gmail.com
-
Kaohsiung, Taiwan
- Recruiting
- E-Da Hospital
-
Contact:
- Yao-Chun Hsu, MD, PhD
- Phone Number: 886975209520
- Email: holdenhsu@gmail.com
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Tung-Hung Su, MD, PhD
- Phone Number: 886972651694
- Email: tunghungsu@gmail.com
-
Taipei, Taiwan
- Not yet recruiting
- Buddhist Tzu-Chi General Hospital Taipei Branch
-
Contact:
- Chia-Chi Wang, MD
- Phone Number: 2317 886266289779
- Email: uld888@yahoo.com.tw
-
Taipei, Taiwan
- Recruiting
- Taipei City Hospital, RENAI Branch
-
Contact:
- Chih-Lin Lin, MD
- Phone Number: 886227099558
- Email: lcl@tpech.gov.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria A. Switching therapy cohort
- Chronic hepatitis B patients receiving oral antiviral therapy (ETV, TDF) for at least 2 years, and fulfil the following NUCs discontinuation criteria (1)HBeAg-positive patients achieving HBeAg seroclearance, and received at least 1-year consolidation therapy (2) HBeAg-negative patients achieving undetectable HBV DNA for more than 1 year (on 3 occasions, 6 months apart)
- After NUC discontinuation, patients had a clinical relapse (HBV DNA > 2000 IU/mL, and ALT > 2x ULN)
- The retreatment regimen switches to TAF (within 3 months of clinical relapse)
B. Historical continuing therapy cohort
- Chronic hepatitis B patients receiving oral antiviral therapy (ETV, TDF) for at least 2 years, and fulfil the following NUCs discontinuation criteria (1) HBeAg-positive patients achieving HBeAg seroclearance, and received at least 1-year consolidation therapy (2) HBeAg-negative patients achieving undetectable HBV DNA for more than 1 year(on 3 occasions, 6 months apart)
- After NUC discontinuation, patients had a clinical relapse (HBV DNA > 2000 IU/mL, and ALT > 2x ULN)
- The patients continued the original regimen (ETV, TDF) for retreatment (within 3 months of clinical relapse)
Exclusion Criteria
- Patients who do not fulfill the discontinuation criteria
- Patients who have HCV, HDV or HIV co-infection
- Patients who discontinue lamivudine, adefovir, or telbivudine therapy
- Patients with liver cirrhosis by ultrasonography and clinical diagnosis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Switching therapy cohort
single arm, open label Patients will receive Vemlidy (tenofovir alafenamide, TAF) 25mg, daily for 48 weeks
|
25mg Tenofovir Alafenamide
Other Names:
|
No Intervention: Historical continuing therapy cohort
By retrospectively review medical records, The patients continued the original regimen (ETV, TDF) for retreatment (within 3 months of clinical relapse)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of virological remission (HBV DNA <20 IU/mL)
Time Frame: 48 weeks
|
We will calculate the rate of virological remission (HBV DNA <20 IU/mL) after retreatment
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of ALT normalization (ALT < 40 U/L) after retreatment
Time Frame: 48 weeks
|
We will calculate the rate of ALT normalization (ALT < 40 U/L) after retreatment
|
48 weeks
|
Rate of HBsAg change after retreatment compared with baseline
Time Frame: 48 weeks
|
We will investigate the rate of HBsAg change after retreatment compared with the baseline HBsAg
|
48 weeks
|
Rate of HBcrAg change after retreatment compared with baseline
Time Frame: 48 weeks
|
We will investigate the rate of hepatitis B core-related antigen (HBcrAg) change after retreatment compared with baseline HBcrAg
|
48 weeks
|
Rate of M2BPGi level change after retreatment compared with baseline
Time Frame: 48 weeks
|
We will investigate the rate of Mac-2 binding protein glycosylation isomer (M2BPGi) level change after retreatment compared with baseline M2BPGi level
|
48 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Tung-Hung Su, MD, PhD, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Hepatitis, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
Other Study ID Numbers
- 201911095MIPD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Hepatitis b
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Zhongshan Hospital Xiamen UniversityUnknownHealthy | Chronic Hepatitis B InfectionChina
-
Tongji HospitalGilead SciencesRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Changhai HospitalCompleted
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
-
Brii Biosciences LimitedVir Biotechnology, Inc.Active, not recruitingChronic Hepatitis B Virus InfectionSingapore, Thailand, Australia, China, Korea, Republic of
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
Clinical Trials on Vemlidy
-
Dong-A ST Co., Ltd.CompletedHepatitis BKorea, Republic of
-
Yonsei UniversityNot yet recruitingPatients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication
-
Gilead SciencesCompletedChronic Hepatitis BUnited States, Hong Kong, Korea, Republic of, Taiwan, United Kingdom, Canada, New Zealand, Italy
-
Gilead SciencesF-star Therapeutics, Inc.TerminatedChronic Hepatitis BKorea, Republic of, Hong Kong
-
Gilead SciencesCompletedChronic Hepatitis BKorea, Republic of, Canada, Taiwan
-
Gilead SciencesCompletedHBV | Chronic HBV InfectionsChina
-
Gilead SciencesCompletedChronic Hepatitis BUnited States, Canada, United Kingdom, Hong Kong, Spain, Taiwan, Korea, Republic of, Italy
-
Gilead SciencesCompletedHBeAg-negative Chronic Hepatitis BHong Kong, United States, United Kingdom, Canada, Australia, Spain, Taiwan, India, Japan, Poland, Romania, Russian Federation, Korea, Republic of, Italy, New Zealand, France, Turkey
-
Gilead SciencesCompletedHBV | Chronic HBV InfectionsChina
-
Gilead SciencesCompletedHBeAg-positive Chronic Hepatitis BHong Kong, Korea, Republic of, United States, Taiwan, United Kingdom, France, Australia, Spain, Bulgaria, Canada, India, Italy, Japan, New Zealand, Poland, Romania, Russian Federation, Singapore, Turkey